While at the Rodman & Renshaw’s 16th Annual Conference in New York City today, we had the opportunity to listen in on more than 60 different presentations. The companies below caught our attention.

Celsion Corp. (NASDAQ: CLSN) is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. For more information, visit www.celsion.com.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is an oncology company developing new treatments for cancer and associated pain. The company’s most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. For more information, visit www.sorrentotherapeutics.com.

Solitario Exploration & Royalty Corp. (NYSE MKT: XPL) is a gold, silver, platinum-palladium, and base metal exploration and royalty company with projects in Brazil, Mexico, Peru and Nevada. Success achieved thus far has been fueled by management’s ability to identify large-potential early stage exploration properties and subsequently leverage these successes into partnerships with senior mining companies. The company currently has significant business relationships with Votorantim Metais and Anglo Platinum. For more information, visit www.solitarioxr.com.

Let us hear your thoughts below: